Passage Bio Inc [PASG] stock is trading at $0.83, up 46.36%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PASG shares have gain 27.42% over the last week, with a monthly amount drifted -17.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Rodman & Renshaw started tracking the stock with Buy rating on September 03, 2024, and set its price target to $7. On March 08, 2022, downgrade downgraded it’s rating to Neutral. Goldman downgraded its rating to a Neutral and decreased its price target to $6 on January 19, 2022. Raymond James initiated its recommendation with a Outperform and recommended $29 as its price target on July 01, 2021. BTIG Research started tracking with a Buy rating for this stock on June 15, 2021, and assigned it a price target of $25. In a note dated March 04, 2021, Goldman upgraded an Buy rating on this stock and boosted its target price from $28 to $30.
Passage Bio Inc [PASG] stock has fluctuated between $0.45 and $1.79 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Passage Bio Inc [NASDAQ: PASG] shares were valued at $0.83 at the most recent close of the market. An investor can expect a potential return of 622.89% based on the average PASG price forecast.
Analyzing the PASG fundamentals
Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -12.61%, Pretax Profit Margin comes in at -11.64%, and Net Profit Margin reading is -11.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -0.73 and Total Capital is -0.79.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6701 points at the first support level, and at 0.5101 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0000, and for the 2nd resistance point, it is at 1.1699.
Ratios To Look Out For
For context, Passage Bio Inc’s Current Ratio is 5.15. Also, the Quick Ratio is 5.15, while the Cash Ratio stands at 1.91.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Dec 27 ’24 when 0.37 million shares were purchased. 10% Owner, ORBIMED ADVISORS LLC completed a deal on Dec 20 ’24 to sell 0.23 million shares. Meanwhile, 10% Owner ORBIMED ADVISORS LLC sold 54181.0 shares on Dec 09 ’24.
